Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06692894 · ClinicalTrials.gov registry record
Defining Inflammatory Markers of Cardiovascular Disease in Patients With Myelodysplastic Syndromes
A clinical trial of Myelodysplastic Syndromes, Adult, sponsored by University of Vermont.
- Recruiting
- Registry status
- 30
- Enrollment target
- 1
- Study location
NCT06692894 is a study of Myelodysplastic Syndromes, Adult that is actively recruiting participants, run by University of Vermont. The registered enrollment target is 30 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06692894, a study of Myelodysplastic Syndromes, Adult, is actively recruiting participants, sponsored by University of Vermont.
- RECRUITING
- Registry status
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Why Is This Research Study Being Conducted? * The study wants to find out why people with a type of blood cancer called myelodysplastic syndromes (MDS) are more likely to have heart problems like heart disease and stroke. * Researchers also want to see if certain proteins related to inflammation in the body can help predict these heart issues in MDS patients. * By understanding this better, researchers hope to find new ways to detect and manage heart disease risks in people with MDS
Conditions Studied
Interventions
- OTHER Observational
Study Locations (1)
Vermont
- University of Vermont - Burlington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2024-11-05 |
| Est. Completion | 2027-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06692894
The ClinicalTrials.gov registry entry for NCT06692894 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Vermont, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Myelodysplastic Syndromes, Adult appearing as the primary indexed condition, and to 1 intervention - of which Observational is the first listed.
NCT06692894 reports 1 study location spanning 1 distinct geographic area - top geographies include Vermont.
Frequently Asked Questions
What is clinical trial NCT06692894 about?
NCT06692894 is a clinical study titled "Defining Inflammatory Markers of Cardiovascular Disease in Patients With Myelodysplastic Syndromes". Why Is This Research Study Being Conducted? * The study wants to find out why people with a type of blood cancer called myelodysplastic syndromes (MDS) are more likely to have heart problems like heart disease and stroke. * Researchers also want to see if certain proteins related to inflammation in...
What is the current status of trial NCT06692894?
This trial is currently recruiting. The enrollment target is 30 participants. The study started on 2024-11-05. Estimated completion is 2027-11.
What conditions does trial NCT06692894 study?
This clinical trial studies the following conditions: Myelodysplastic Syndromes, Adult.
What interventions are being tested in trial NCT06692894?
The interventions under investigation include: Observational (OTHER).
Who is sponsoring clinical trial NCT06692894?
This trial is sponsored by University of Vermont, which has 162 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06692894 being conducted?
This trial has 1 study location across Vermont. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.